Cost analysis of therapy for patients with multiple sclerosis (MS) in Poland

Pharmacological Reports

Volumn 60, Issue 5, 2008, Pages 632-644

  Matschay, Arleta ^a   Nowakowska, Elzbieta ^a   Hertmanowska, Hanka ^b   Kus, Krzysztof ^a   Czubak, Anna ^a  

^a POZNAN UNIVERSITY OF MEDICAL SCIENCES   (Poland)

^b Regional Hospital Lutycka in Pozna   (Poland)

Author keywords

Cost analysis; Interferon; Methylprednisolone; Multiple sclerosis

Indexed keywords

INTERFERON BETA SERINE; METHYLPREDNISOLONE SODIUM SUCCINATE;

ADULT; ARTICLE; COST BENEFIT ANALYSIS; COST EFFECTIVENESS ANALYSIS; COST OF ILLNESS; DISEASE COURSE; DRUG EFFICACY; EXPANDED DISABILITY STATUS SCALE; FEMALE; FUNCTIONAL ASSESSMENT; HUMAN; IMMUNOMODULATION; MAJOR CLINICAL STUDY; MALE; MULTIPLE SCLEROSIS; PHYSICAL CAPACITY; POLAND; RECURRENCE RISK;

EID: 57849131187     PISSN: 22995684     EISSN: 22995684     Source Type: Journal    
DOI: None     Document Type: Article

References (45)

1. AISM L'Associazione Italiana Sclerosi Multipla) I costi della SM [online] Available from URL: http://www.aism.it [accessed 2004 Sep 6].
2. Amato MP, Battaglia MA, Caputto D, Fattore G, Gerzeli S, Pitaro M, Reggio A et al.: The cost of multiple sclerosis: a cross-sectional, multicenter cost-of-illness study in Italy. J Neurol, 2002, 249, 152-163.
3. Asche CV, Ho E, Chan B, Coyte PC: Economic consequences of multiple sclerosis for Canadians. Acta Neurol Scand, 1997, 95, 268-274.
4. Beck RW: On behalf of The Optic Neuritis Study Group. The effect of corticosteroids for acute optic neuritis on the subsequent development of multiple sclerosis. N Engl J Med, 1993, 329, 1764-1769.
5. Bruck W, Porada P, Poser S, Rieckmann P, Hanefeld F, Kretzschmar HA, Lassmann H: Monocyte/macrophage differentiation in early multiple sclerosis leasion. Ann Neurol, 1995, 38, 788-796.
6. Bruck W, Schmied M, Suchanek G, Bruck Y, Breitschopf H, Poser S, Piddlesden S et al: Oligodendrocytes in the early course of multiple sclerosis. Ann Neurol, 1994, 35, 65-73.
7. Catanzaro M, Weinert C: Economic status of families living with multiple sclerosis. Int J Rehabil Res, 1992, 15, 209-218.
8. Ebers GC, Paty DW: Natural history studies and applications to clinical trials. In: Multiple Sclerosis. Ed. Paty DW, Ebers GC, Philadelphia, FA Davis Co, 1997, 192-228.
9. European Study Group on interferon β-1b in Secondary Progressive MS. Placebo-controlled multicentre randomized trial of interferon β-1b in treatment of secondary progressive multiple sclerosis. Lancet, 1998, 352, 1491-1497.
10. Gran B, Hemmer B, Vergelli M, McFarland HF, Martin R: Molecular mimicry and multiple sclerosis: degenerate T-cell recognition and the induction of auto-immunity. Ann Neurol, 1999, 45, 559-567.
11. Hauser SL: Multiple sclerosis and other demyelinating disease. In: Harrison's Principals of International Medicine, 13th edn. Ed. Isselbacher KJ, Braunwald E, Wilson JD et al., New York, McGraw-Hill, 1994, 2287-2295.
12. Holmes J, Madwick T, Bates D: The cost of multiple sclerosis. Br J Med Economics, 1995, 8, 181-193.
13. INFB Multiple Sclerosis, University of British Columbia MS/MRI Analysis Group: Interferon beta-lb in the treatment of MS: final outcome of the randomized controlled trial. Neurology, 1995, 45, 1277-1285.
14. Iskedjian M, Walker JH, Gray T, Vincente C, Einarson TE, Gehshan A: Economic evaluation of Avonex® (interferon beta-Ia) in patients following a single demyelinating event. Mult Scler, 2005, 11, 542-551.
15. Jacobs LD, Beck RW, Simon JH, Kinkel LP, Brownscheidle CM, Murray TJ, Simonian NA et al.: Intramuscular interferon beta-1a therapy initiated during a first demyelinating event in multiple sclerosis. N Engl J Med, 2000, 343, 898-904.
16. Jacobs LD, Cookfair DL, Rudick RA, Herndon RM, Richert JR, Salazar AM, Fischer JS et al.: Intramuscular interferon beta-1a for disease progression in exacerbating-remitting multiple sclerosis. Ann Neurol, 1996, 39, 285-294.
17. Johnson KP, Brooks BR, Cohen JA, Ford CC, Goldstein J, Lisak RP, Myers LW et al.: Copolymer 1 reduces relapse rate and improves disability in relapsing-remitting multiple sclerosis: results of a phase III multicenter, double-blind, placebo-controlled trial. Neurology, 1995, 45, 1268-1276.
18. Kappos L, Weinshenker B, Pozzilli C, Thompson AJ, Dahlke F, Beckmann K, Polman C et al.: Interferon beta-1b in secondary progressive MS. Neurology, 2004, 63, 1779-1787.
19. Kendrick M, Johnson KI: Long term treatment of multiple sclerosis with interferon-beta may be cost effective. Pharmacoeconomics, 2000, 18, 45-53.
20. Kobelt G, Jönsson L, Miltenburger C, Jönsson B: Cost-utility analysis of interferon beta-1B in secondary progressive multiple sclerosis using natural history disease data. Int J Technol Asses Health Care, 2002, 18, 127-138
21. Kurtzke JF: Rating neurological impairment in multiple sclerosis: an expanded disability status scale (EDSS). Neurology, 1983, 33, 1444-1452.
22. Li H, Newcombe J, Groome NP, Cuzner ML: Characterization and distribution of phagocytic macrophages in multiple sclerosis plaques. Neuropathol Appl Neurobiol, 1993, 19, 214-223.
23. Martino G, Hartung HP: Immunopathogenesis of multiple sclerosis: the role of T cells. Curr Opin Neurol, 1999, 12, 209-321.
24. McDonald WI, Compston A, Edan G, Goodkin D, Hartung HP, Lublin FD, McFarland HF et al.: Recommended diagnostic criteria for multiple sclerosis: guidelines from the international panel on the diagnosis of multiple sclerosis. Ann Neurol, 2001, 50, 121-127.
25. McGown L, McWhinnie L: MS patient survey cost and reimbursement of treatment. The cost of multiple sclerosis. Concordia University Pharmaceutical Management Centre 1995.
26. Miller DE, Simon JH, Rudick RA, Jacobs LD: Determinants of brain atrophy in relapsing Multiple Sclerosis. Neurology, 1999, 52, A357, PO4.101.
27. Miller DH, Thompson AJ, Morrissey SP, MacManus DG, Moore SG, Kendall BE, Moseley IF et al.: High dose steroids in acute relapses of multiple sclerosis: MRI evidenee for a possible mechanism of therapeutic effect. J Neurol Neurosurg Psychiatry, 1992, 55, 450-453.
28. Milo R, Panitch H: Additive effects of COP-1 and INF-Beta on immune response to myelin basic protein. Neurology, 1994, 44, 212.
29. Murphy N, Confavreux C, Haas J, Konig N, Roullet E, Sailer M, Swash M et al.: Economic evaluation of multiple sclerosis in the UK, Germany and France. Pharmacoeconomics, 1998, 13, 607-622.
30. Narayana PA, Doyle YJ, Lai D, Wolinsky JS: Serial proton magnetic resonance spectroscopic imaging, contrast-enhanced magnetic resonance imaging and quantitative lesion volumetry in multiple sclerosis. Ann Neurol, 1998, 43, 56-71.
31. Pashos CL, Klein EG, Wanke LA: On behalf of ISPOR Lexicon, 1st edn. International Society for Pharmaco-economics and Outcomes Research, Princeton, NJ, 1998.
32. Paty DW, Li DKB: On behalf of The UCB MS/MRI Study Group and the INFB Multiple Sclerosis Study Group. Interferon beta-1b is effective in relapsing-remitting multiple sclerosis. II. MRI analysis results of a multicenter, randomized, double-blind, placebo-controlled trial. Neurology, 1993, 43, 662467.
33. Pozzilli C, Romano S, Cannoni S: Epidemiology and current treatment of multiple sclerosis in Europe today. J Rehabil Res Dev, 2002, 39, 175-186.
34. Practice Advisory on Selection of Patients with Multiple Sclerosis for Treatment with Betaseron. Report of q Quality Standards Subcommittee of the American Academy of Neurology. Neurology, 1994, 44, 1537-1540.
35. PRISMS (Prevention of Relapses and Disability by Interferon beta-1a Subcutaneously in Multiple Sclerosis) Study Group. Randomized double-blind placebo-controlled study of interferon β-la in relapsing/remitting multiple sclerosis. Lancet, 1998, 352, 1498-1504.
36. Pugliatti M, Rosati G, Carton H, Riise T, Drulovic J, Vécsei L, Milanov I: The epidemiology of multiple sclerosis in Europe. Eur J Neurology, 2006, 13, 700-722.
37. Reske D, Schoppe S, Broicher C, Petereit HF: The immunomodulatory properties of in vitro immunoglobulins are dose-dependent. Acta Neurol Scand, 2003, 108, 267-273.
38. Rudick RA, Goodkin DE, Jacobs LD, Cookfair DL, Herndon RM, Richert JR, Salazar AM et al.: Impact of interferon beta-1a on neurological disability in relapsing multiple sclerosis. Neurology, 1997, 49, 358-363.
39. Runmarker B, Andersen O: Prognostic factors in a multiple sclerosis incidence cohort with twenty-five years of follow up. Brain, 1993, 116, 117-134.
40. Sorensen TL, Ransohoff RM: Ethiology and pathogenesis of multiple sclerosis. Semin Neurol, 1998, 18, 287-294.
41. The Canadian Burden of Illness Study Group. Burden of illness of multiple sclerosis: Part I: Cost of illness. Can J Neurol Sci. 1998, 25, 23-30.
42. The INFB Multiple Sclerosis Study Group: Interferon beta-1b is effective in relapsing-remitting multiple sclerosis. 1. Clinical results of a multicenter, randomized, double-blind, placebo-controlled trial. Neurology, 1993, 43, 655-661.
43. Tremlett H: Oral versus intravenous methylprednisolone in acute relapse of multiple sclerosis. Lancet, 1997, 349, 1696-1697.
44. Waxman SG: Multiple sclerosis as a neuronal disease. Arch Neurol, 2000, 57, 22-24.
45. Weinshenker BG, Rice GP, Noseworthy JH, Carriere W, Baskerville J, Ebers GC: The natural history of multiple sclerosis: a geographically based study. 3. Multivariate analysis of predictive factors and models of outcome. Brain, 1991, 114, 1045-1056.